Company intelligence / Profile preview
Lycera
Ann Arbor, Michigan, United Stateslycera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lycera was a biopharmaceutical company focused on developing novel oral small molecule immunomodulators for autoimmune diseases. Its lead programs targeted the Th17/ROR-gamma pathway and cellular bioenergetics. The company demonstrated preclinical efficacy and safety improvements over standard-of-care agents but does not appear to have advanced any candidates into late-stage clinical trials before becoming inactive.
- Therapeutic areas
- GastroenterologyOncologyImmunologyDermatology
- Modalities
- Small moleculesMonoclonal antibodiesDesigner drugsCannabinoids
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Lycera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lycera.